Viral Vector Genetic Adjuvants for Dual CD40 and STING Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines, particularly for diseases like HIV and cancer, fail to induce effective cellular immune responses due to the immune system's evasion strategies employed by cancer cells and infectious agents, and conventional adjuvants are inadequate for enhancing these responses.
Innovation Solution
Viral vectors encoding genetic adjuvants that mimic CD40 activation and activate the STING pathway, comprising nucleic acid sequences for antigens, full-length latent membrane protein 1 (LMP1) of Epstein Barr virus, and a fusion protein with human IPS1, optimized for human expression, to enhance cellular immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional adjuvants (e.g., aluminum salts) are used, then vaccine effectiveness is improved, but cellular immune response enhancement is insufficient
Solution Approach 1:
The invention changes the molecular parameters of adjuvants by using genetic adjuvants (DNA/RNA sequences) that encode immune regulatory molecules, transitioning from conventional aluminum salts to molecule-based adjuvants that can be precisely engineered for specific immune pathway activation
Solution Approach 2:
The invention creates composite genetic adjuvant systems combining multiple immune regulatory molecules (e.g., CD40 ligand, STING agonists, cytokines) within single viral vector constructs, enabling simultaneous activation of multiple immune pathways for enhanced cellular immunity
2Productivity
If viral vectors encode multiple genetic adjuvants (LMP1 and IPS1 fusion protein), then immune response enhancement is improved, but vector complexity increases
Solution Approach 1:
The invention merges multiple genetic adjuvant functions into a single viral vector construct, combining LMP1 and IPS1 fusion protein encoding sequences along with antigen genes in one integrated vector system, simplifying delivery while maintaining enhanced immune activation
Solution Approach 2:
The viral vector is designed as a multi-functional platform that simultaneously delivers antigen genes and multiple genetic adjuvant genes (LMP1, IPS1 fusion), enabling a single vector to perform antigen presentation, immune pathway activation, and cytokine induction functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The viral vectors significantly enhance immune responses by activating both CD40-like and STING pathways, leading to improved cellular immune responses against cancer and infections, simplifying development, enhancing efficacy, and reducing long-term genetic sequence expression risks.
Implementation Method 1
the transmembrane domains of LMP1 spontaneously form clusters that allow the aggregation of the IPS1 into intracytoplasmic clusters
Implementation Method 2
Activation of IFN-β promoter stimulator (IPS1, also referred to as MAVS, VISA, or Cardif) generates potent T cell responses via the STING (stimulator of interferon genes) pathway
Implementation Method 3
Viral vectors encoding genetic adjuvants that mimic CD40 activation and activate the STING pathway
Data Source
Figure 1
Figure 2
Figure 3(a)
AI summary
Viral vectors are provided for use as genetic immunotherapeutic agents, including preventive and therapeutic vaccines as well as compositions to enhance cellular immune responses and innate immune responses. The vectors are particularly useful for treating or preventing cancer and infectious diseases. The vectors include lentiviral vectors that encode one or more antigens, a combination of adjuvants, and optionally may encode one or more soluble and secreted checkpoint inhibitor molecules. The adjuvants include latent membrane protein 1 (LMP1) from Epstein Barr virus and a fusion protein including LMP1 with in which the intracytoplasmic domain has been replaced by human IPS1 or a variant thereof capable of activating the STING pathway. The vector-encoded sequences are codon optimized for human expression.